Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer

Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer

The cyclin D-cyclin-dependent kinase (CDK) 4/6 pathway controls the cell cycle machinery by regulating the G1-to-S-phase transition. Dysregulation of this pathway, resulting in increased cellular proliferation, is frequently observed in a variety of human cancers. Activation of cyclin D-CDK 4/6 path...

Full description

Saved in:
Bibliographic Details
Main Authors: Tamojit Chaudhuri, K Govind Babu, K C Lakshmaiah, Lokanatha Dasappa, Linu Abraham Jacob, M C Suresh Babu, A H Rudresha, K N Lokesh, L K Rajeev
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Abemaciclib
palbociclib
ribociclib
selective cyclin-dependent kinase 4/6 inhibitors
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=15;epage=20;aulast=Chaudhuri
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=15;epage=20;aulast=Chaudhuri

Similar Items